AlprostadilvsGonadorelin

Alprostadil is synthetic prostaglandin E1 (PGE1), a 20-carbon oxygenated fatty acid derived from dihomo-gamma-linolenic acid (DGLA) through the cyclooxygenase pathway. It acts locally on penile vascular and trabecular smooth muscle through two prostaglandin E receptor subtypes: EP2 and EP4, both of which are Gs-coupled GPCRs that increase intracellular cAMP upon activation.

Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple targets in smooth muscle cells to produce relaxation. PKA phosphorylates myosin light chain kinase (MLCK), reducing its affinity for the calcium-calmodulin complex and decreasing its ability to phosphorylate myosin light chains — the final step in smooth muscle contraction. PKA also activates calcium-ATPase pumps and opens potassium channels, reducing intracellular calcium concentration. The net effect is relaxation of both the helicine arterioles (which supply blood to the corpora cavernosa) and the trabecular smooth muscle (which forms the spongy erectile tissue). As these relax, blood flows into the sinusoidal spaces of the corpora cavernosa, expanding the tissue against the tunica albuginea and compressing the subtunical veins — trapping blood and producing an erection.

The critical distinction of alprostadil's mechanism is its direct, local action independent of central sexual arousal pathways and independent of nitric oxide. PDE5 inhibitors (sildenafil, etc.) work by preventing cGMP breakdown downstream of nitric oxide release, which requires sexual arousal to generate the initial NO signal. Alprostadil generates its own second messenger (cAMP) at the injection site regardless of arousal state, which is why it produces erections reliably even in patients with neurogenic erectile dysfunction (spinal cord injury, radical prostatectomy) where the nerve-mediated NO pathway is damaged. The extremely rapid pulmonary metabolism (80% cleared in a single pass through the lungs) ensures that systemic effects are minimal when administered locally.

Gonadorelin is a synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to endogenous gonadotropin-releasing hormone (GnRH) produced by hypothalamic neurons in the arcuate nucleus. It binds to GnRH receptors (GnRHR), a Gq/11-coupled GPCR on pituitary gonadotroph cells, activating phospholipase C, generating IP3 and DAG, and raising intracellular calcium to trigger the release of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The critical pharmacological principle of gonadorelin is that its biological effect depends entirely on the pattern of administration. Pulsatile administration (mimicking the hypothalamic GnRH pulse generator, which fires approximately every 60-90 minutes) maintains gonadotroph sensitivity and produces physiological LH/FSH release. This pulsatile pattern is essential because GnRHR undergoes rapid desensitization and internalization upon continuous stimulation. Continuous or high-frequency GnRH exposure causes receptor downregulation, depleting the gonadotroph cell surface of functional receptors, and paradoxically suppresses LH and FSH — the principle exploited by GnRH agonist depot formulations (leuprolide, goserelin) used for chemical castration in prostate cancer and endometriosis.

In the context of testosterone replacement therapy (TRT), gonadorelin is used to maintain intratesticular testosterone (ITT) and spermatogenesis, which would otherwise be suppressed by exogenous testosterone through negative feedback. Exogenous testosterone signals the hypothalamus and pituitary to reduce GnRH, LH, and FSH secretion, causing the testes to atrophy and sperm production to cease. By providing pulsatile GnRH stimulation, gonadorelin keeps the LH signal active, maintaining Leydig cell testosterone production and Sertoli cell-supported spermatogenesis. This has made gonadorelin an increasingly popular alternative to HCG for fertility preservation during TRT, especially since the FDA's reclassification of HCG as a biologic restricted compounding availability.